
What's Abridge?
Abridge is an American medical artificial intelligence company founded in 2018 and headquartered in Pittsburgh, Pennsylvania. Co-founded by Shivdev Rao, M.D., Florian Metze, Ph.D., and Sandeep Konam, the company is focused on developing apps that utilize artificial intelligence technology to record and summarize medical conversations. Its core product converts patient-physician conversations into structured clinical notes in real-time and seamlessly integrates with electronic medical record (EMR) systems.
The company has raised more than $212 million through multiple rounds of funding, including a $150 million Series C round co-led by Lightspeed Venture Partners and Redpoint Ventures.2025 In February, Abridge announced the closing of a $250 million Series D financing round, valuing the company at $2.5 billion dollars. Its products have access to more than 100 health systems across the U.S., and its customers include well-known organizations such as Duke Health and Mayo Clinic.
Abridge's core business
- Products & Services: Abridge's core product is aAI's medical conversation recording tool, which converts doctor-patient conversations into structured clinical notes in real time and synchronizes them directly to electronic medical record (EMR) systems. The technology accurately extracts key medical information (e.g., diagnosis, medication recommendations, etc.) through natural language processing and machine learning algorithms, helping doctors to reduce time-consuming paperwork and improve diagnosis and treatment efficiency.
- Technical characteristics: Abridge's AI technology utilizes data extracted from over 1.5 million medical conversations to improve the speed and accuracy of medical records. Its platform supports 28 languages and has access to more than 100 health systems across the U.S., with clients including Duke Health, Mayo Clinic, and other well-known organizations.
Abridge's market performance and competitiveness
- market position: Abridge tops the Forbes AI 50 list in 2024 with its technological breakthroughs and commercial landing ability, becoming a benchmark company in the healthcare AI field.
- Competitive advantages: Abridge's competitive advantage lies in the innovative nature of its technology and its focus on the practicality of improving the recording of medical conversations, as well as its strong R&D team and close collaboration with clinicians. In addition, Abridge focuses on data privacy compliance, system compatibility and clinical scenario adaptation to meet the specific needs of the healthcare industry.
Abridge's Business Model and Partners
- business model: Abridge generates revenue by providing subscription services to health systems, and the company expects its ARR (annual recurring revenue) to reach $50 million in 2024.
- cooperative partner: Abridge has established partnerships with technology companies such as NVIDIA to leverage their computing resources and expertise to expand their artificial intelligence systems. In addition, Abridge has established partnerships with several healthcare organizations and insurance companies to drive widespread adoption of its products.
data statistics
Relevant Navigation

Valued at over $200 million, specializing in app building platforms, founded in California in 2019

Cohere
Valued at over $5 billion, focused on AI big model R&D, founded in 2019 and headquartered in Toronto, Canada

Replicate
Valued at $350 million, focused on AI applications, founded in 2019 and headquartered in California, USA

Crusoe
Founded in 2018 and valued at over $2.8 billion, it is focused on providing sustainable, low-cost energy solutions for AI data centers using innovative energy technologies.

Synthesia
Valued at $1 billion, focused, founded in 2017, based in London, UK

Midjourney
Founded in 2021 and valued at nearly $10 billion, it focuses on enabling high-quality, artistically stylized text-to-image generation through generative artificial intelligence technology.

Tome
Valued at $350 million, focused on AI-powered multimedia and software, founded in 2020, based in California, USA

Cradle
Valued at over $100 million, focused on AI to assist in designing and engineering proteins 2021, based in Delft, Netherlands
No comments...